Live tape
Top 8, mentions 7d10,902TSLA2,518 mentions▲ +0.06SPCX2,098 mentions▲ +0.08GOOGL1,366 mentions▲ +0.04CRWV1,207 mentions▲ +0.04NVDA1,073 mentions▲ +0.07QQQ1,037 mentions▲ +0.05META826 mentions▲ +0.05NBIS777 mentions▲ +0.07

Equity · Healthcare

VCYT

NASDAQ

Veracyte (VCYT)

$59.12 +0.19% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for VCYT to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $4.8B
P/E (TTM) 42.2
52-week range $23.01 – $60.51
Avg volume 257.8K

as of Jul 17, 2026

Veracyte (VCYT) insider trades

SEC Form 4 · last 90 days · newest reported trade 19 Oct 2026

In the 90 days to 21 Oct 2026, Veracyte insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Oct 2025, show no open-market purchase.

Open-market buys 0
Open-market sells 7
Net sold $1.39M
Non-trade filings 6
Date Insider Type Shares Value
19 Oct 2026 Bhanji Muna Director Sell 1,864 $81K
21 Sep 2026 Leite John Global Chief Commercial Off Sell 4,015 $161K
14 Sep 2026 Holstein Jens Director Sell 5,000 $205K
04 Sep 2026 Chambers Rebecca Chief Financial Officer Sell 3,652 $157K
04 Sep 2026 Febbo Phillip G. Chief Scientific & Med Officer Sell 13,110 $564K
04 Sep 2026 McGuire Annie EVP, General Counsel Sell 3,254 $140K
01 Sep 2026 Bhanji Muna Director Sell 1,864 $80K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
02 Sep 2026 Chambers Rebecca Chief Financial Officer Tax withheld 3,603 $162K
02 Sep 2026 Febbo Phillip G. Chief Scientific & Med Officer Tax withheld 3,639 $163K
02 Sep 2026 Leite John Global Chief Commercial Off Tax withheld 3,961 $178K
02 Sep 2026 McGuire Annie EVP, General Counsel Tax withheld 3,215 $144K
02 Sep 2026 Stapley Marc Chief Executive Officer Tax withheld 8,782 $394K
02 Sep 2026 Wygant Jonathan VP, Chief Accounting Officer Tax withheld 1,361 $61K

Veracyte (VCYT) reported financials

SEC EDGAR XBRL SEC EDGAR

Veracyte reported revenue of $517.1M for the fiscal year ended 31 Dec 2025. Net income over the same period was $66.4M.

Figure Reported Period
Revenue $517.1M 31 Dec 2025 fiscal year
Net income $66.4M 31 Dec 2025 fiscal year
Diluted EPS $0.82 31 Dec 2025 fiscal year
Total assets $1.5B 30 Jun 2026 at period end
Total equity $1.4B 30 Jun 2026 at period end

Veracyte (VCYT) earnings

SEC EDGAR

Veracyte last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.31; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.31 —
31 Mar 2026 Q1 2026 $0.35 —
31 Dec 2025 FY 2025 $0.82 —
30 Sep 2025 Q3 2025 $0.24 —
30 Jun 2025 Q2 2025 −$0.01 —
31 Mar 2025 Q1 2025 $0.09 —
31 Dec 2024 FY 2024 $0.31 —
30 Sep 2024 Q3 2024 $0.19 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Veracyte (VCYT) institutional holders (13F)

SEC Form 13F SEC EDGAR

10 of the 45 institutional funds we track reported a Veracyte position for the quarter ended 30 Jun 2026 — a combined $262.0M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
ARK Investment Management Held (±25%) −24.8% shares 2,295,951 $134.8M
Point72 Asset Management Added +52.5% shares 737,804 $43.3M
Fisher Asset Management Held (±25%) −4.8% shares 700,592 $41.1M
D. E. Shaw & Co. Added +880.3% shares 413,037 $24.3M
AQR Capital Management Added +65.7% shares 149,648 $8.8M
Millennium Management New position 71,982 $4.2M
Bridgewater Associates Trimmed −36.4% shares 58,289 $3.4M
Man Group Trimmed −87.5% shares 22,291 $1.3M
Marshall Wace Trimmed −79.1% shares 6,367 $374K
Balyasny Asset Management Trimmed −98.0% shares 5,874 $345K

Veracyte (VCYT) fails-to-deliver

SEC CNS data SEC

On 21 Sep 2026, 7,692 shares of Veracyte failed to deliver (about $306K) — the latest of 4 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
21 Sep 2026 7,692 $306K 0.010%
18 Sep 2026 23,770 $964K 0.030%
17 Sep 2026 8,065 $311K 0.010%
16 Sep 2026 19,925 $800K 0.025%
11 Sep 2026 3,492 $147K 0.004%

Congressional trades in Veracyte (VCYT)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Veracyte is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 12 Nov 2025.

Date Member Type Amount
12 Nov 2025 filed 15 Dec 2025 Gilbert Ray Cisneros, Jr. house · Democrat–CA Sale $1K–$15K
16 Jun 2025 filed 10 Jul 2025 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
16 Oct 2023 filed 11 Nov 2023 Josh Gottheimer house · Democrat–NJ Purchase $1K–$15K
15 Sep 2023 filed 15 Oct 2023 Josh Gottheimer house · Democrat–NJ Sale $1K–$15K
10 Apr 2023 filed 19 May 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K
23 Dec 2020 filed 11 Jan 2021 Gilbert Ray Cisneros, Jr. house · Democrat–CA Sale $1K–$15K
08 Dec 2020 filed 07 Jan 2021 Josh Gottheimer house · Democrat–NJ Sale $1K–$15K
29 Oct 2020 filed 05 Nov 2020 Gilbert Ray Cisneros, Jr. house · Democrat–CA Sale $1K–$15K

Veracyte (VCYT): frequently asked questions

From live data

Have Veracyte insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, Veracyte insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 1 Oct 2025, show no open-market purchase. A further 6 filings were grants, awards, gifts or exercises rather than open-market trades.

How many institutions hold Veracyte?

10 of the 45 institutional funds we track reported a Veracyte position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Veracyte had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Veracyte is dated 21 Sep 2026, when 7,692 shares failed to deliver.

When did Veracyte last report earnings?

Veracyte last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.31; no next date is announced in SEC filings yet.

What exchange is Veracyte listed on?

Veracyte trades on NASDAQ under the ticker VCYT.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings